<DOC>
	<DOC>NCT00531479</DOC>
	<brief_summary>This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive Aspergillosis.</brief_summary>
	<brief_title>Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis</brief_title>
	<detailed_description />
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Anidulafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy; Diagnosis of possible, probable, or proven invasive aspergillosis. Patients with aspergilloma or chronic aspergillosis Receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis Anticipated survival of less than 5 days or Karnofsky score &lt;=20</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>